acute-myeloid-leukemia

Documents about acute-myeloid-leukemia

• Comparison of VA (Venetoclax, Azacitidine), VACl (VA, Cladribine), VACh (VA, Chidamide), and Alternating VACl/VACh in Newly Diagnosed Acute Myeloid Leukemia#878671ClinicalTrials.gov
• Dasatinib Combined With Chemotherapy in Relapsed t(8;21) Acute Myeloid Leukemia With KIT D816 Mutation#885820ClinicalTrials.gov
• An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.#1046905ClinicalTrials.gov
• Evaluation of a New Anti-cancer Immunotherapy After Chemotherapy in Adult Patients With Acute Myeloid Leukemia (AML)#300262ClinicalTrials.gov
• IDH1/IDH2 Mutation Frequency in Acute Myeloblastic Patients#993379ClinicalTrials.gov
• A Safety and Tolerability Extension Trial Assessing Repeated Dosing of Anti-KIR (1-7F9) Human Monoclonal Antibody in Patients With Acute Myeloid Leukaemia#966741ClinicalTrials.gov
• Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome#881346ClinicalTrials.gov
• Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression#807651ClinicalTrials.gov
• Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies#831072ClinicalTrials.gov
• Total-Body Irradiation and Chemotherapy Followed By Donor Bone Marrow Transplant in Treating Young Patients With Hematologic Cancer#830629ClinicalTrials.gov
• Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia#836844ClinicalTrials.gov
• An Open-label Phase II Study of Lorvotuzumab Mertansine#879723ClinicalTrials.gov
• The Efficacy of Therapy in Patients With Acute Myeloid Leukemia and Down Syndrome in Russia#839781ClinicalTrials.gov
• A Phase 1, Open Label Study of Intravenous GSK3745417 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Determine RP2D & Schedule in Participants With Relapsed or Refractory Myeloid Malignancies Including AML and HR MDS#888513ClinicalTrials.gov
• Surface CD81 supports leukemia stem cell function and reveals a therapeutic vulnerability in acute myeloid leukemia#137418HAL (France)
• S0125, Chemotherapy, Total-Body Irradiation, and Peripheral Stem Cell Transplantation in Treating Older Patients With Acute Myeloid Leukemia#245517ClinicalTrials.gov
• Next Generation Sequencing (NGS) in Familial Acute Myeloid Leukemia and Myelodisplastic Syndromes#874954ClinicalTrials.gov
• Safety and Clinical Activity Study of Combination Azacitidine and Avelumab in Patients With Acute Myeloid Leukemia (AML) and Minimal Residual Disease (MRD)#862664ClinicalTrials.gov
• MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib#1044966ClinicalTrials.gov
• Haploidentical Stem Cell Transplant for Treatment Refractory Hematological Malignancies#902104ClinicalTrials.gov
• A Study of the Safety and Pharmacokinetics of RO6839921, An MDM2 Antagonist, in Patients With Advanced Cancers, Including Acute Myeloid Leukemia.#882616ClinicalTrials.gov
• Evaluation of Online Patient Education Materials for Acute Myeloid Leukemia.#172092NCBI PubMed Central
• Leveraging Immunotherapy in Acute Myeloid Leukemia Treatment: Opportunities and Challenges.#404437NCBI PubMed Central
• Sulindac for Patients With AML#886302ClinicalTrials.gov
• Ribavirin and Hedgehog Inhibitor With or Without Decitabine in AML#1009707ClinicalTrials.gov
• The Patient Cohort of the National Center for Precision Medicine in Leukemia#851332ClinicalTrials.gov
• Study Comparing Imatinib With Chemotherapy as Induction in Elderly Patients With Philadelphia Positive Acute Lymphoblastic Leukemia (ALL)#852868ClinicalTrials.gov
• Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)#839992ClinicalTrials.gov
• UCMSC-Exo for Chemotherapy-induced Myelosuppression in Acute Myeloid Leukemia#877244ClinicalTrials.gov
• Safety and Efficacy Study of Nilotinib Combined With Mitoxantrone, Etoposide, and High-dose Cytarabine Induction Chemotherapy Followed by Consolidation for Patients With C-kit Positive Acute Myeloid Leukemia#897112ClinicalTrials.gov
• Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases#914299ClinicalTrials.gov
• Phenylbutyrate Plus Azacitidine in Treating Patients With Acute Myeloid Leukemia, Myelodysplasia, Non-Hodgkin's Lymphoma, Multiple Myeloma, Non-small Cell Lung Cancer, or Prostate Cancer#882538ClinicalTrials.gov
• Natural Killer Cell (CYNK-001) Infusions in Adults with AML#898774ClinicalTrials.gov
• Allo-HSCT With Alternative Donor in Treatment of Hematologic Malignancy#838927ClinicalTrials.gov
• An Exercise Trial for Acute Myeloid Leukaemia (AML) Patients Undergoing Induction Chemotherapy#905387ClinicalTrials.gov
• Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine & Mitoxantrone for Untreated AML & High-Grade Myeloid Neoplasm#1010010ClinicalTrials.gov
• Phase I Study of FXS0683 in the Treatment of Blood Tumors#831651ClinicalTrials.gov
• UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep#843050ClinicalTrials.gov
• A Study of the Effectiveness of Venetoclax in Combination With Azacitidine or Decitabine in an Outpatient Setting in Patients With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy#830942ClinicalTrials.gov
• GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies#810075ClinicalTrials.gov
• Collecting and Storing Tissue From Young Patients With Cancer#1009757ClinicalTrials.gov
• Efficacy and Safety of MTBF Conditioning Regimen for Salvageable Allo-HSCT in the Treatment of R/R AML#894897ClinicalTrials.gov
• A Multicenter Trial Evaluating Efficacy and Safety of A Reduced Venetoclax Exposure To Seven Days Versus Standard Continuous Venetoclax Exposure Combined With Azacitidine in Treatment Naïve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Intensive Induction#858424ClinicalTrials.gov
• Study of Molecular and Genetic Abnormalities in Patients With Myeloid Neoplasms#813124ClinicalTrials.gov
• 2321GCCC: CRD3874-SI in Patients With Relapsed/Refractory AML#802218ClinicalTrials.gov
• Molecular Characterization of Carbapenemase-Producing Enterobacterales#834688ClinicalTrials.gov
• CPX-351 Real-World Effectiveness and Safety Study#916807ClinicalTrials.gov
• Comparative efficacy of venetoclax and hypomethylating agents in acute myeloid leukemia treatment: a meta-analysis of clinical trials and Real-World outcomes#355443Repositorio Institucional de la Universidad de Burgos (RIUBU)
• A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT#907907ClinicalTrials.gov
• GRACE: A Phase 1/2a Study of VTRU200 in Relapsed/Refractory AML, High-risk MDS, DLBCL Post CART Failure and Advanced Solid Tumors#633715ClinicalTrials.gov